Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CHLOROQUINE PHOSPHATE vs ARALEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Chloroquine is a 4-aminoquinoline that acts as a blood schizonticide. It inhibits heme polymerase in malaria parasites, preventing the conversion of toxic heme to hemozoin, leading to accumulation of toxic heme and parasite death. It also has anti-inflammatory and immunomodulatory effects via inhibition of toll-like receptors and cytokine production.
Chloroquine, a 4-aminoquinoline, accumulates in acidic organelles such as food vacuoles of malaria parasites, inhibiting heme polymerase and preventing the conversion of toxic heme to hemozoin. It also interferes with DNA synthesis and repair by intercalating into DNA. Additionally, it has immunomodulatory effects via inhibition of Toll-like receptors and cytokine production.
Treatment of uncomplicated malaria due to chloroquine-sensitive Plasmodium species,Prophylaxis of malaria in areas with chloroquine-sensitive strains,Treatment of extraintestinal amebiasis (as an adjunct),Treatment of discoid lupus erythematosus (off-label),Treatment of rheumatoid arthritis (off-label),Treatment of porphyria cutanea tarda (off-label)
Treatment of uncomplicated malaria caused by susceptible strains of Plasmodium vivax, P. malariae, P. ovale, and P. falciparum,Prophylaxis of malaria in areas with chloroquine-sensitive P. falciparum,Treatment of extraintestinal amebiasis (as amebicide) and giardiasis (off-label),Disease-modifying antirheumatic drug (DMARD) for rheumatoid arthritis and lupus erythematosus (off-label)
600 mg base (1 g phosphate) orally once daily for 2 days, then 300 mg base (500 mg phosphate) orally once daily for 3 days for malaria. For extraintestinal amebiasis: 600 mg base (1 g phosphate) orally once daily for 2 days, then 300 mg base (500 mg phosphate) orally once daily for 2-3 weeks.
Adults: 500 mg (300 mg base) orally once weekly on the same day each week for prophylaxis of malaria; 1 g (600 mg base) orally initially, followed by 500 mg (300 mg base) at 6, 24, and 48 hours for treatment of acute malaria.
Terminal elimination half-life: 30-60 days (range 20-100 days); prolonged due to extensive tissue distribution and slow release from lysosomes.
Terminal elimination half-life ranges from 30 to 60 days (mean ~45 days) due to extensive tissue binding; clinical context: prolonged half-life allows weekly dosing for malaria prophylaxis.
Hepatic metabolism via CYP2C8 and CYP3A4 to major metabolite desethylchloroquine; other minor metabolites. Renal excretion of parent drug and metabolites.
Chloroquine is extensively metabolized in the liver via cytochrome P450 enzymes, primarily CYP2C8 and CYP3A4, to active metabolites such as desethylchloroquine. It has a long elimination half-life of approximately 1-2 months.
Renal: 50-70% as unchanged drug; hepatic/biliary: 20-30% as metabolites; fecal: up to 20%.
Primarily renal (approximately 70% as unchanged drug); minor biliary/fecal (about 10-20%).
50-60% bound to plasma proteins, primarily albumin.
Approximately 50-60% bound; primarily to albumin and alpha-1-acid glycoprotein.
Vd: 100-150 L/kg (range 50-200 L/kg); extremely large indicating extensive tissue penetration and accumulation.
Very large, 100-200 L/kg; extensive tissue distribution (liver, spleen, kidney, lungs, melanin-containing tissues).
Oral: 80-90% (rapidly absorbed from GI tract); bioavailability is nearly complete with food enhancing absorption.
Oral: 80-90%.
For Cr Cl <10 m L/min: use 50% of normal dose. For Cr Cl 10-50 m L/min: no adjustment required. For intermittent hemodialysis: no supplemental dose needed.
For malaria prophylaxis: No adjustment necessary. For treatment: If Cr Cl < 10 m L/min, reduce dose by 50%.
Severe impairment (Child-Pugh C): maximum 300 mg base (500 mg phosphate) every 12 hours; monitor for toxicity. Mild to moderate impairment: no adjustment needed.
No formal guidelines; use caution in severe hepatic impairment due to potential accumulation. Consider dose reduction in Child-Pugh class C.
For malaria: 10 mg base/kg (16.7 mg phosphate/kg) orally once daily for 2 days, then 5 mg base/kg (8.3 mg phosphate/kg) orally once daily for 3 days. Maximum single dose: 600 mg base (1 g phosphate). For extraintestinal amebiasis: 10 mg base/kg (16.7 mg phosphate/kg) orally once daily for 2-3 weeks (max 300 mg base/day).
Prophylaxis: 5 mg/kg base (8.3 mg/kg salt) orally once weekly, max 300 mg base. Treatment: 10 mg/kg base (16.7 mg/kg salt) orally initially, followed by 5 mg/kg base at 6, 24, and 48 hours, max 600 mg base on day 1.
No specific dose adjustment; use with caution due to increased risk of QT prolongation and accumulation with renal impairment. Consider lower initial dose and monitor renal function.
No specific adjustments; consider age-related renal impairment and potential increased risk of QT prolongation. Monitor for cardiac effects.
None explicitly required in current FDA labeling for chloroquine; however, serious adverse effects such as irreversible retinal damage, cardiac toxicity, and hypoglycemia are well-documented. Not receiving a black box warning in standard product labeling.
Retinopathy: Irreversible retinal damage including retinopathy and visual disturbances; risk increases with cumulative dose and duration of use; contraindicated in patients with pre-existing retinopathy; baseline and periodic ophthalmologic exams required.
Retinopathy: irreversible retinal damage with prolonged use; baseline and periodic ophthalmologic exams recommended for chronic therapy.,Cardiac toxicity: QTc prolongation, ventricular arrhythmias, cardiomyopathy; avoid in patients with pre-existing cardiac conditions or concurrent QTc-prolonging drugs.,Hypoglycemia: can cause severe hypoglycemia, especially in diabetics.,Neuropsychiatric effects: seizures, psychosis, suicidal ideation.,Hematologic toxicity: agranulocytosis, aplastic anemia (rare).,Hepatotoxicity: elevated liver enzymes, hepatic failure.,Ototoxicity: irreversible hearing loss.,G6PD deficiency: hemolytic anemia risk with acute hemolysis.
Retinopathy risk with prolonged use; cardiac effects including conduction disorders (e.g., QT prolongation) and cardiomyopathy; exacerbation of psoriasis and porphyria; neuropsychiatric effects (e.g., psychosis, seizures); hematologic toxicity (eg, agranulocytosis, aplastic anemia); hypoglycemia; myopathy; ototoxicity. Use with caution in hepatic or renal impairment, G6PD deficiency, and pregnancy (benefit vs risk).
Hypersensitivity to chloroquine or any 4-aminoquinoline,Pre-existing retinopathy or visual field changes,Pregnancy (especially first trimester) due to potential fetal harm; use for malaria only if benefit outweighs risk,Lactation: caution, excreted in breast milk,G6PD deficiency (relative contraindication; may cause hemolysis)
Hypersensitivity to chloroquine or 4-aminoquinolines; pre-existing retinopathy of any etiology; concurrent use with other agents causing retinal toxicity (e.g., hydroxychloroquine, tamoxifen); porphyria; psoriasis (relative, may exacerbate); neuromyopathy (relative); severe hepatic or renal impairment (relative).
No specific food restrictions. Absorption enhanced by food; take with meals to reduce GI upset. Avoid grapefruit juice if QT prolongation concern.
Avoid grapefruit juice as it may increase chloroquine levels. No other significant food interactions.
Chloroquine phosphate crosses the placenta. First trimester: limited data suggest no major increase in congenital malformations, but risk cannot be excluded. Second and third trimesters: no specific fetal risks documented at standard doses; however, high doses (e.g., for malaria treatment) may cause retinal toxicity or ototoxicity. Overall, considered low teratogenic risk, but benefit-risk assessment required.
Pregnancy category C. First trimester: No conclusive evidence of major malformations in human studies, but animal studies show embryotoxicity and fetotoxicity. Second and third trimesters: Risk of sensorineural hearing loss, vestibular damage, and retinal toxicity in the fetus if used for prolonged periods or at high doses; accumulation in fetal ocular tissues reported.
Chloroquine is excreted into breast milk in small amounts (M/P ratio approximately 0.3-0.5). Infant dose is estimated <5% of maternal weight-adjusted dose. No adverse effects in breastfed infants reported. Considered compatible with breastfeeding.
Excreted in breast milk in small amounts (M/P ratio approximately 0.44). American Academy of Pediatrics considers compatible with breastfeeding, but caution is advised in infants with glucose-6-phosphate dehydrogenase deficiency or hemolytic disease. Monitor infant for rash, retinal changes, and hemolysis.
No dose adjustment required for prophylaxis or treatment of malaria in pregnancy (standard adult dosing). For autoimmune indications (e.g., lupus, rheumatoid arthritis), maintain lowest effective dose (e.g., 250 mg daily of chloroquine base equivalent). Increased clearance in pregnancy may necessitate therapeutic drug monitoring in rare cases, but standard dosing is typically sufficient.
No specific dose adjustment recommended for pregnancy; pharmacokinetic changes (increased volume of distribution, decreased plasma concentrations) may require therapeutic drug monitoring, but empirical dose adjustments are not established. Use lowest effective dose and shortest duration.
Chloroquine has a narrow therapeutic index; toxicity can cause retinopathy, especially with cumulative doses >460g base. Baseline and annual eye exams are mandatory. For acute malaria, may need loading dose. Contraindicated in G6PD deficiency due to hemolysis risk. QT prolongation possible; avoid with other QT-prolonging drugs.
Chloroquine (Aralen) can cause retinal toxicity; cumulative dose should not exceed 200g. Use with caution in G6PD deficiency. Can prolong QTc interval; avoid with other QTc-prolonging drugs.
Take exactly as prescribed; do not miss doses or double up.,Can cause blurred vision; avoid driving until vision clears.,Report vision changes, hearing loss, or unusual bleeding immediately.,May cause GI upset; take with food or milk.,Finishing full course is critical even if symptoms improve.,Use sunscreen; may increase sensitivity to sunlight.
Take with food to reduce gastrointestinal upset.,Do not exceed prescribed dose; overdose can be fatal.,Report any vision changes immediately; regular eye exams are required.,Avoid alcohol as it may increase risk of liver toxicity.,Inform your doctor if you have a history of heart rhythm problems.
"The coadministration of alogliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, with chloroquine may lead to increased plasma concentrations of chloroquine. This occurs because alogliptin potentially inhibits CYP2C8 and/or CYP3A4, the cytochrome P450 enzymes responsible for chloroquine metabolism. As a result, patients may be at higher risk for chloroquine-related adverse effects such as cardiac arrhythmias (QT prolongation), retinopathy, and hypoglycemia."
"Chloroquine inhibits CYP2C8, CYP2D6, and CYP3A4, key enzymes responsible for the metabolism of nilotinib. This inhibition can significantly increase nilotinib plasma concentrations, elevating the risk of severe adverse effects such as QTc prolongation, hepatotoxicity, and myelosuppression. Concurrent use may also exacerbate the risk of cardiotoxicity, including arrhythmias and sudden cardiac death, due to additive effects on cardiac repolarization."
"Amiloride, a potassium-sparing diuretic, may reduce the antihypertensive efficacy of chloroquine, an antimalarial agent. This interaction arises from amiloride's inhibition of renal tubular sodium reabsorption, which can alter electrolyte balance and potentially blunt the hypotensive effects of chloroquine, leading to suboptimal blood pressure control. In clinical practice, this may result in diminished antihypertensive response, requiring dose adjustments or alternative therapies."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CHLOROQUINE PHOSPHATE vs ARALEN, answered by our medical review team.
CHLOROQUINE PHOSPHATE is a Antimalarial that works by Chloroquine is a 4-aminoquinoline that acts as a blood schizonticide. It inhibits heme polymerase in malaria parasites, preventing the conversion of toxic heme to hemozoin, leading to accumulation of toxic heme and parasite death. It also has anti-inflammatory and immunomodulatory effects via inhibition of toll-like receptors and cytokine production.. ARALEN is a Antimalarial that works by Chloroquine, a 4-aminoquinoline, accumulates in acidic organelles such as food vacuoles of malaria parasites, inhibiting heme polymerase and preventing the conversion of toxic heme to hemozoin. It also interferes with DNA synthesis and repair by intercalating into DNA. Additionally, it has immunomodulatory effects via inhibition of Toll-like receptors and cytokine production.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CHLOROQUINE PHOSPHATE and ARALEN depend on the specific clinical indication. These are both Antimalarial agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CHLOROQUINE PHOSPHATE is: 600 mg base (1 g phosphate) orally once daily for 2 days, then 300 mg base (500 mg phosphate) orally once daily for 3 days for malaria. For extraintestinal amebiasis: 600 mg base (1 g phosphate) orally once daily for 2 days, then 300 mg base (500 mg phosphate) orally once daily for 2-3 weeks.. The standard adult dose of ARALEN is: Adults: 500 mg (300 mg base) orally once weekly on the same day each week for prophylaxis of malaria; 1 g (600 mg base) orally initially, followed by 500 mg (300 mg base) at 6, 24, and 48 hours for treatment of acute malaria.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CHLOROQUINE PHOSPHATE and ARALEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CHLOROQUINE PHOSPHATE is classified as Category C. Chloroquine phosphate crosses the placenta. First trimester: limited data suggest no major increase in congenital malformations, but risk cannot be excluded. Second and third trime. ARALEN is classified as Category C. Pregnancy category C. First trimester: No conclusive evidence of major malformations in human studies, but animal studies show embryotoxicity and fetotoxicity. Second and third tri. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.